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To systematically review the literature comparing the efficacy and safety of dexmedetomi-
dine and midazolam when used for procedural sedation.
Materials and Methods
We searched MEDLINE, EMBASE and COCHRANE for clinical trials comparing dexmede-
tomidine and midazolam for procedural sedation up to June 20, 2016. Inclusion criteria: clini-
cal trial, human subjects, adult subjects (18 years), article written in English, German,
French or Dutch, use of study medication for conscious sedation and at least one group
receiving dexmedetomidine and one group receiving midazolam. Exclusion criteria: patients
in intensive care, pediatric subjects and per protocol use of additional sedative medication
other than rescue medication. Outcome measures for efficacy comparison were patient and
clinician satisfaction scores and pain scores; outcome measures for safety comparison
were hypotension, hypoxia, and circulatory and respiratory complications.
Results
We identified 89 papers, of which 12 satisfied the inclusion and exclusion criteria; 883
patients were included in these studies. Dexmedetomidine was associated with higher
patient and operator satisfaction than midazolam. Patients receiving dexmedetomidine
experienced less pain and had lower analgesic requirements. Respiratory and hemody-
namic safety were similar.
Conclusions
Dexmedetomidine is a promising alternative to midazolam for use in procedural sedation.
Dexmedetomidine provides more comfort during the procedure for the patient and clinician.
If carefully titrated, the safety profiles are similar.







Citation: Barends CRM, Absalom A, van Minnen B,
Vissink A, Visser A (2017) Dexmedetomidine
versus Midazolam in Procedural Sedation. A
Systematic Review of Efficacy and Safety. PLoS
ONE 12(1): e0169525. doi:10.1371/journal.
pone.0169525
Editor: Daqing Ma, Imperial College London,
UNITED KINGDOM
Received: July 13, 2016
Accepted: December 19, 2016
Published: January 20, 2017
Copyright: © 2017 Barends et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: The authors received no specific funding
for this work.
Competing Interests: The authors have declared
that no competing interests exist.
Introduction
Procedural sedation can provide more comfort for the patient and an easier procedure for the
clinician for painful or unpleasant diagnostic or therapeutic procedures. It may be preferred
over general anesthesia due to physiological, financial and logistical considerations,.
Midazolam is one of the classic sedatives for procedural sedation. While midazolam is
thought to cause minimal hemodynamic effects, it does have the potential to cause loss of air-
way reflexes, respiratory depression, and even apnea [1]. If an effective, reliable and safe seda-
tive could be used in general practice, this would benefit a wide range of patients, especially
those who are frail, anxious, severely phobic or uncooperative.
Dexmedetomidine (an alpha2-adrenergic agonist) is a relatively new drug, which can also
be used for procedural sedation. It has sedative and anxiolytic properties and is known for its
analgesic potential owing to a reduction of sympathetic tone. Dexmedetomidine induces dose-
dependent effects, ranging from minimal to deep sedation. Moreover, except at doses that
cause very deep sedation or general anesthesia, the sedation is reversible. The patient can be
easily roused to a lucent state, but when left undisturbed will fall back into a state very similar
to natural sleep. These are unique properties among the sedative medications in common use.
Dexmedetomidine does not impair the respiratory drive per se and seldom causes apnea.
However, it has been shown to impair the respiratory responses to hypoxia and hypercapnia
[2] and can cause hemodynamic effects such as hypertension, hypotension and bradycardia
[1].
Many studies have compared aspects of the safety and efficacy of midazolam and dexmede-
tomidine, but the results have not yet been systematically reviewed. Therefore, the aim of our
systematic review was to systematically review the current literature on the relative efficacy
and safety of dexmedetomidine and midazolam when used as monosedatives for conscious,
procedural sedation. We included studies of all types of surgical or diagnostic procedures.
The objective of this systematic review was to answer the following research question: does
dexmedetomidine result in more efficacious and safer sedation compared to midazolam in the
periprocedural period for adult patients undergoing procedural sedation?
Methods
Literature Search
We searched the Cochrane, Pubmed and Embase databases to identify adult human clinical
trials comparing the sedative efficacy and/or safety of dexmedetomidine versus midazolam.
Studies that compared both drugs without routine use of other sedative medications—other
than for rescue from inadequate sedation or analgesia—were eligible for inclusion.
For the Pubmed search (last accessed on June 20, 2016) we used the following search
strategy: (("dexmedetomidine"[MeSH Terms] OR "dexmedetomidine"[All Fields]) AND
("midazolam"[MeSH Terms] OR "midazolam"[All Fields]) AND sedation[All Fields]) AND
"humans"[MeSH Terms]). The Embase database was searched with a comparable search
strategy as used for Pubmed (last accessed June 20, 2016): (’dexmedetomidine’/exp OR dexme-
detomidine AND (’midazolam’/exp OR midazolam) AND (’conscious sedation’/exp OR ’con-
scious sedation’)). The Cochrane library was searched for relevant reviews using the following
search terms: dexmedetomidine AND midazolam AND sedation. There was no limit on the
years considered.
The papers thus identified were screened by two authors (CB, AV) by title and abstract for
eligibility for inclusion (Fig 1). The resulting papers were read in full (by CB and AV) and the
reference lists were scanned for additional material.
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Data extraction and assessment of risk of bias was done by the same two authors (CB, AV).
Pilot forms were used to extract unfiltered data on all described outcome measures related to
efficacy and safety. The outcome measures for the review were selected by means of team dis-
cussion (CB, AV, AA, BM). The selected outcome measures were placed onto forms for col-
lecting data from the studies reviewed.
Study selection
Study selection was based on the following criteria:
Participants: adults receiving procedural sedation
Type of intervention: dexmedetomidine use for procedural sedation
Type of comparison: midazolam use for procedural sedation
Study types: randomized controlled clinical trials
We excluded studies where dexmedetomidine or midazolam was given as part of intensive
or critical care and any studies including children. Also excluded were studies where addi-
tional medication with sedative properties was given other than as rescue medication.
The Jadad score [3] was used to assess the quality of trials. Disagreements on Jadad scoring
were solved primarily by discussion and secondarily by consultation with a third author (AA).
We planned to discuss any information from low quality studies (Jadad score < 3) with all
authors before using it for conclusions for this review. Statistical data from low quality studies
was not included in our statistical analyses.
Patient and operator satisfaction scores and pain scores were used to compare efficacy. If
these outcome measures were not expressed numerically in scores or ratings, we used the ver-
bal descriptions provided in the studies.
To compare the safety of dexmedetomidine and midazolam we recorded all reports of
hypotension and hypoxia. When no explicit mention of these events was present, reports of
hemodynamic and respiratory complications were discussed by three authors (CB, AV, AA) to
evaluate their eligibility for inclusion in the results. If the absence of complications was explic-
itly mentioned or if it was explicitly stated that there was no need for intervention, the inci-
dence of hypotension or hypoxia was assumed to be zero.
Statistical analysis
To compare the incidences of hypotension and respiratory adverse events, we isolated the
studies and patient groups in which patients received either dexmedetomidine or midazolam
for subgroup analysis. These pooled incidences of hypotension and respiratory adverse events
were compared with the Chi-square test.
Results
The results of our search strategy according to the PRISMA method [4] are summarized in Fig
1 (Fig 1). We identified a total of 89 papers, of which 12 satisfied the inclusion and exclusion
criteria. Because not all studies reported all of the predefined outcomes, our conclusions were
based on subgroups of studies reporting the relevant outcomes.
Description of studies
Twelve publications were direct comparisons of dexmedetomidine with midazolam (Fig
1, Table 1). The included studies were heterogenous with respect to dosages, administra-
tion regimens and scoring systems. In 2 of the 12 publications the subjects were human volun-
teers, not patients. One study investigated hemodynamic changes during sedation with
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dexmedetomidine or midazolam (or propofol) [5], the other evaluated the effects of these seda-
tives on the perception of various painful stimuli [6]. A priori power analysis was mentioned
in 4 of the 12 studies.
Of the 12 included studies, 4 were given a final JADAD score of 2 or lower [5,6,12,15]
(Table 2). Although all 12 studies were randomized, not all were double-blind trials. Two were
volunteer studies in which the authors did not use blinding as this was deemed not feasible or
not appropriate [5,6]. The three other studies without double-blinding were from Demiraran
et al, Hashiguchi et al. and Liao et al. [10,12,14]. In the first study the patients and the observers
were blinded, but not the physician performing the procedure. In the latter two there was no
blinding (Table 2).
Efficacy: satisfaction, sedation, analgesia and amnesia
Patient satisfaction. Eight studies (n = 597 subjects) measured patient satisfaction by
means of numerical rating scales or questionnaires with Likert scales (Table 3). Four of these
studies (n = 214) reported dexmedetomidine to be superior in this respect to midazolam
[7,8,11,16]. The other four studies (n = 383) [9,10,13,14] did not show a significant difference
in patient satisfaction between the drugs (Table 4).
Analgesia. Eight studies (n = 577) reported on the comparative analgesic effects of dexme-
detomidine and midazolam (Table 3). Two of them (n = 134) reported that dexmedetomidine
had a greater analgesic effect [7,8]. The other six studies (n = 443) showed no difference in
analgesic potency between the drugs [9,10,13–16] (Table 4).
In two studies in which dexmedetomidine treatment resulted in higher patient satisfaction,
this treatment was also associated with better analgetic properties compared to midazolam
[7,8]. Midazolam has no analgesic effect and can even lower pain thresholds [6]. Likewise, the
Fig 1. PRISMA Diagram.
doi:10.1371/journal.pone.0169525.g001
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studies resulting in no preference for dexmedetomidine or midazolam also reported no differ-
ence in analgetic potential [9,10,13,14].
Clinician satisfaction. Nine studies (n = 637) reported either clinician satisfaction or a
measure of ease of performance of the procedure (Table 3). Four of them (n = 174) reported a
significant difference in favor of dexmedetomidine in terms of clinician satisfaction with the
sedation [7,10,11,16]. In the other five studies (n = 463) dexmedetomidine and midazolam
resulted in equal clinician satisfaction [8,9,13–15] (Table 4).
Kaya et al. reported that dexmedetomidine use, when compared to midazolam, was associ-
ated with more patients reaching the desired level of sedation [13]. Muttu et al. and Cheung
et al. [9,15] mentioned that several patients became restless, aggressive or agitated after mida-
zolam administration. This reaction was not reported in dexmedetomidine-treated patients in
any of the included studies.
Safety
Respiratory effects. In 11 studies (n = 767) both the number of patients included and the
number of respiratory adverse events or complications was reported [5,7–16]. We found no
difference in the incidence of respiratory events in the pooled results from the high quality
studies. We found 20 events of hypoxia among 281 dexmedetomidine-treated patients, com-
pared to 24 events among 280 midazolam-treated patients (p = 0.52; Table 5).
Hemodynamic effects. Except for two studies [5,6], all studies reported the incidence of
hemodynamic adverse events. Among ten studies (n = 737) the incidence was 0% for both
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groups in seven studies [7–11,15,16], while in three studies the number of adverse events was
very low and the difference between groups was not statistically significant [12–14] (Table 5).
The data from the eight good quality studies was pooled, showing a similar incidence of
hypotension: 10 events of hypotension among 281 dexmedetomidine-treated patients com-
pared to 7 events among 280 midazolam-treated patients (p = 0.80) [7–11,13,14,16] (Table 5).
Finally, two studies [12,14] reported that hypertension occurred as an unwanted reaction in
midazolam-treated patients, whereas the hypertensive response to stress was attenuated in the
dexmedetomidine-treated patients.
Discussion
For adult patients undergoing procedural sedation, dexmedetomidine results in more effica-
cious sedation than midazolam in the periprocedural period. The safety profile of both drugs
appears to be similar. We found that dexmedetomidine has potential benefits over midazolam
when used for procedural sedation. No studies reported that patients or clinicians were more
satisfied with the result of midazolam sedation, whereas several studies found dexmedetomi-
dine use to be associated with greater patient and clinician satisfaction and greater analgetic
potential. The safety of both drugs seems to be similar with respect to respiratory or hemody-
namic complications.
Patient and clinician satisfaction
Patients expect procedural sedation to provide them with comfort during an otherwise stress-
ful or painful period. Alleviation of pain and discomfort is an important determinant for
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patient satisfaction scores. This may explain the higher patient satisfaction scores for dexmede-
tomidine in several studies [7,8]. Dexmedetomidine has intrinsic analgetic potential, whereas
midazolam can actually increase pain perception [6]. Only Ustun et al. reported greater patient
satisfaction without better analgesia for dexmedetomidine [16]. This was a crossover study in
which patients were treated sequentially with both sedatives.
All studies, except for the volunteer studies of Fro¨lich et al. [5,6], used additional local anes-
thesia. This is in accordance with the generally accepted view that sedatives for conscious seda-
tion should never be used without additional analgesia.
Midazolam also provides amnesia. Although this may be preferred by some patients, for
instance those with dentophobia, amnesia could also be considered undesirable for this group
of patients. These patients aim to alleviate their fear through gradual exposure, and amnesia
prevents this learning effect.
Like patients, clinicians in the selected studies tended to have a preference for dexmedeto-
midine. Based on their additional comments in these studies, this preference might be
explained by the improved cooperation of patients treated with dexmedetomidine and the
absence of paradoxical reactions in this group [9,11,15]. The better cooperation of patients
treated with dexmedetomidine is due to the unique properties of dexmedetomidine sedation.
Table 3. Study and outcome overview.
Studies n
Hypotension
-reporting on incidence of hypotension 10 737
-without significant difference 10 737
-with greater incidence in DEX treated pts 0 0
-with greater effect in MDZ treated pts 0 0
Respiratory events
-reporting on incidences of respiratory events 11 767
-without significant difference 11 797
-with greater incidence in DEX treated pts 0 0
-with greater incidence in MDZ treated pts 0 0
Efficacy
-reporting on patient satisfaction 8 597
-without significant difference 4 214
-with greater pat. satisfaction in DEX treated pts 4 383
-with greater pat. satisfaction in MDZ treated pts 0 0
-reporting on clinician satisfaction 9 637
-without significant difference 5 463
-with greater clinician satisfaction in DEX treated pts 4 174
-with greater clinician satisfaction in MDZ treated pts 0 0
-reporting on analgesia 8 577
-without significant difference 6 443
-with better analgesia scores in DEX treated pts 2 134
-with better analgesia scores in MDZ treated pts 0 0
- reporting on predictability/stability 11 1002
-without significant difference 3 180
-with better predictability in DEX treated pts 8 822
-with better predictability in MDZ treated pts 0 0
DEX: dexmedetomidine; MDZ: midazolam.
doi:10.1371/journal.pone.0169525.t003
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The patients can be woken to a lucid state from what seems like natural sleep, to follow instruc-
tions and return to a sedated state when left undisturbed.
Paradoxical reactions are a rare but well known side effect of benzodiazepines. The occur-
rence of restlessness, agitation and even aggression is very disturbing to the patient as well as
to the clinician. The etiology is unclear but children and the elderly are more prone. Although
the reported incidence is <1% these reactions can prevent clinicians from completing the pro-
cedure. Moreover, the outright hostility seen in some patients exhibiting a paradoxical reaction
to midazolam presents a danger to both patient and clinician [17]. Dexmedetomidine is not
known to cause these reactions and no such reactions were reported in dexmedetomidine-
treated patients in the included studies.
All of the above findings can be explained from the pharmacodynamics of both drugs. Mid-
azolam produces its effects through the GABAa receptors and inhibits the excitatory reaction
of the brain to stimuli [1]. Dexmedetomidine does not produce such central cerebral inhibi-
tion; it affects the locus coeruleus. This is a central neural pathway playing a key role in induc-
ing natural sleep. Dexmedetomidine has been shown to have the ability to improve natural
sleep when given to intensive care patients in both low, non-sedative dosages [18] and in seda-
tive dosages [19]. Dexmedetomidine also lowers sympathetic tone. It’s mechanism of action
lowers fear and anxiety, whereas midazolam inhibits a reaction of the patient to uninhibited
stimuli. This may explain why sedation with dexmedetomidine is preferred by many patients
over midazolam, which is in line with the crossover study of Ustun et al. [16].
Safety
Respiration. In the pooled results dexmedetomidine and midazolam did not differ in
terms of respiratory safety. This was surprising because midazolam is well known for causing
respiratory depression [1], and we expected that dexmedetomidine treatment would result in
fewer cases of hypoxia. Most of the included studies had careful infusion protocols for both
drugs. And although midazolam has a rapid onset time of 2 to 3 minutes, the effect site con-
centration peaks only after approximately 13 minutes [20,21]. Repeat boluses may be given too
early, which can lead to overdosing and hypoxia.
Table 4. Results for Patient Satisfaction, Clinician Satisfaction, Analgesia and Sedation Predictability/Consistency.
Patient Satisfaction Clinician Satisfaction Analgesia SPCR
n Parameter Result Parameter Result Parameter Result
Alhashemi et al. [7] DEX versus MDZ 44 VRS/LS DEX VRS/LS Scale DEX VRS/LS Scale DEX MDZ
Apan et al. [8] DEX versus MDZ 90 BR DEX VRS/LS Scale NS VASpain DEX NR
Cheung et al. [9] DEX versus MDZ 60 NRS NS NRS and VRS NS NRS NS DEX
Demiraran et al. [10] DEX versus MDZ 50 VAS NS VAS DEX VASpain NS NR
Fan et al. [11] DEX versus MDZ 60 VAS DEX VRS/LS Scale DEX NR NS
Fro¨lich et al. [5] DEX versus MDZ 60 NR NR NR NR
Fro¨lich et al. [6] DEX versus MDZ 86 NR NR NR NR
Hashiguchi et al. [12] DEX versus MDZ 100 NR NR NR NS
Kaya et al. [13] DEX versus MDZ 75 BR NS VRS/LS Scale NS VASpain NS NS
Liao et al. [14] DEX versus MDZ 198 BR NS VAS NS VASpain NS NR
Muttu et al. [15] DEX versus MDZ 40 NR VRS/LS Scale NS VASpain NS DEX
Ustun et al. [16] DEX versus MDZ 20 VAS DEX VRS/LS Scale DEX VASpain NS NS
SPCR: SedationPredictability/Consistency Rating; VRS/LS:Verbal Rating Score/Likert Scale; BR: Binary rating; VASpain: Visual Analogue Scale for pain;
NRS: Numeric Rating Scale; UAA: use of additional analgesia; ISAS: Iowa satisfaction with Anesthesia Score; NR:Not Reported.
doi:10.1371/journal.pone.0169525.t004
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Hypotension. Dexmedetomidine has a reputation of causing hypotension, which is some-
times preceded paradoxically by hypertension. In contrast, midazolam is known for its hemo-
dynamic stability. However, the hypotensive effect of dexmedetomidine can be mitigated by
preventing rapid infusion and by not using bolus dosing. High peak plasma levels are responsi-
ble for the complex hemodynamic effects of dexmedetomidine [22]. In all studies the loading
dose of dexmedetomidine was infused slowly. Alternatively, intranasal administration of dex-
medetomidine avoids high peak plasma levels but still results in adequate plasma levels after
uptake, as shown by Iirola et al. [23]. Moreover, the usefulness of intranasal administration for
procedural sedation has been demonstrated by Zhang et al. and Nooh et al. [24,25].
Careful dosing, preferably by titration, is the key to procedural sedation. Within the con-
fines of carefully protocollized studies, dexmedetomidine (when used with slow loading
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dosages) and midazolam (in a careful infusion regimen) would appear to have similar safety pro-
files. For general practice, this would require intravenous access and infusion pumps for titration,
and appropriate monitoring would still be needed. When patients are sedated with dexmedeto-
midine, they remain rousable. However, it should be remembered that like midazolam, dexme-
detomidine has moderately slow pharmacokinetics, so that during the recovery period, the
patient may be sleepy when not stimulated. As with midazolam, close observation is necessary
for a period of time before discharge commensurate with the pharmacokinetics of the agent.
Dexmedetomidine, however, seems to yield better results with respect to patient and clinician
satisfaction. And the possibility of using this drug safely with intranasal administration may be
very useful for office-based procedural sedation. The safe use of dexmedetomidine in the general
population, and more specifically the frail or the elderly should be the subject of further investiga-
tion before this treatment can be used in the office-based or nursing home-based care setting.
Limitations. The included studies varied widely with respect to dosing regimens, proce-
dures and outcome measures. Also, not all studies reported in enough detail on these outcome
measures. This prevented us from performing more formal meta-analyses.
We excluded studies where analgesics with an additional sedative effect were given other
than as rescue medication and placebo-controlled studies where midazolam served as rescue
medication. This led to the exclusion of many papers studying dexmedetomidine versus mida-
zolam for conscious sedation. However, the exclusion of these studies allowed for a more pre-
cise comparison of the effects of both drugs without accounting for numerous (unpredictable)
pharmacological interactions.
We included four studies of moderate to low quality[5,6,12,15]. Fro¨lichs studies [5,6] do
compare both drugs but not for procedural sedation.The conclusions of none of these studies
conflict the information from this review. Therefore the effect their results have on our con-
clusions is minimal and non-conflicting. We isolated their results from statistical analysis. Re-
calculation without this isolation did not change the outcome for the subgroup analyses.
Midazolam causes profound amnesia. The amnesic effect appears at lower dosages and is
more apparent than the sedative effect. This amnesia could have confounded results when
patient questionnaires are used after midazolam treatment.
The frail and elderly are an underrepresented group in these studies. With only one study
including some ASA 3 patients or a substantial number of patients aged over 60, the safety and
efficacy of dexmedetomidine compared to midazolam for use in procedural sedation in frail
patients has not been well assessed [8]. Su et al. [26] have shown in a recent publication how
the use of low-dose dexmedetomidine for sedation in the elderly in the ICU is safe and has a
preventive effect on the development of delirium after surgery. The occurrence of delirium is
of concern in the treatment of elderly people and the possibility to prevent it from occurring
may prove to be another benefit of the use of dexmedetomidine in procedural sedation.
Conclusion
We have shown that dexmedetomidine has advantages over midazolam in terms of reliability,
analgesia and patients’ and clinicians’ satisfaction. Moreover, within the scope of this review,
dexmedetomidine and midazolam appear to have a similar cardio-respiratory safety profile
when both are carefully titrated. Combined with the use of local anesthesia, dexmedetomidine
provides a good alternative for midazolam for procedural sedation.
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